International enterprises from pharmaceutical sector and unfair competition

Main Article Content

Mariusz Sagan
Wojciech Wiśniewski

Abstract

Multinational enterprises increasingly exploit their institutional advantages by consciously influencing institutions in the expansion market in such a way as to protect corporate interests. To a large extent, this can apply to multinational pharmaceutical companies operating in highly regulated markets, both on the demand and the supply side. The aim of the study was to analyze the actions taken by global pharmaceutical corporations present on the Polish market to influence the institutions of national regulators in order to prevent unfair and unethical competition. The study was of a qualitative nature and covered three very large pharmaceutical entities in Poland. The surveyed companies actively tried to co-create the institutional environment of the target country, in this case the Polish market. At the same time, to a much lesser extent, they took actions to limit unfair competition by means of their institutional advantages, relying primarily on the use of traditional competitive advantages concept.

Downloads

Download data is not yet available.

Article Details

How to Cite
Sagan, M., & Wiśniewski , W. . (2020). International enterprises from pharmaceutical sector and unfair competition. Kwartalnik Nauk O Przedsiębiorstwie, 57(4), 49–58. https://doi.org/10.33119/KNoP.2020.57.4.5
Section
Articles

References

Brycz B., Dudycz T. (2010), Case study jako popularna metoda w naukach o zarządzaniu, „Kwartalnik Nauk o Przedsiębiorstwie”, nr 3.

Ginsburg G.S., McCarthy J.J. (2011), Personalized medicine: revolutionizing drug discovery and patient care, „Trends in Biotechnology”, No 11.

Masi J.A. (2016), Innovation in the pharmaceutical industry: New estimates of R&D costs, „Journal of Health Economics”, Vol. 47, No. 1, p. 20-33.

Sagan M. (2016), Instytucjonalne zaangażowanie korporacji międzynarodowych a trwała przewaga konkurencyjna, „Ekonomika i Organizacja Przedsiębiorstwa”, nr 11, s. 31-32.

Sagan M. (2018), Przewagi instytucjonalne przedsiębiorstw międzynarodowych, „Ekonomika i Organizacja Przedsiębiorstwa”, nr 3, s. 46-48.

Saha C.N., Bhattacharya S. (2011), Intellectual property rights: An overview and implications in pharmaceutical industry, „Journal of Advanced Pharmaceutical and Technological Research”, nr 6.

Lehman B. (2018), The Pharmaceutical Industry and the Patent System, https://users.wfu.edu/mcfallta/DIR0/pharma_patents.pdf (dostęp 21.11.2020).

Second Patent Cliff Lies Ahead for Pharma With $251 Billion in Sales at Risk by 2024, https://www.centerforbiosimilars.com/news/second-patent-cliff-lies-ahead-for-pharma-with-251-billion-in-sales-at-risk-by-2024 (dostęp 5.11.2018).